Watchlist Price Alert

Ginkgo Bioworks Inc. (DNA)

NYSE: DNA · Real-Time Price · USD

7.55

0.07 (0.94%)

At close: Jun 04, 2025, 3:59 PM

7.58

0.30%

After-hours: Jun 04, 2025, 07:56 PM EDT

0.94% (1D)

Bid	7.48
Market Cap	442.21M
Revenue (ttm)	237.42M
Net Income (ttm)	-472.07M
EPS (ttm)	-8.91
PE Ratio (ttm)	-0.85
Forward PE	-1.78
Analyst	Sell

Ask	7.58
Volume	632,704
Avg. Volume (20D)	1,251,503
Open	7.74
Previous Close	7.48
Day's Range	7.49 - 7.78
52-Week Range	5.00 - 22.60
Beta	1.29

About DNA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DNA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

4 weeks ago

+14.73%

Ginkgo Bioworks shares are trading higher after th... Unlock content with Pro Subscription

1 month ago

+11.23%

Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.

News

6 days ago · accessnewswire.com

Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...

1 week ago · businesswire.com

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundr...

2 weeks ago · businessinsider.com

23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.

2 weeks ago · marketwatch.com

23andMe sells its most valuable asset. Regeneron promises keep your DNA private.

Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the th...

2 weeks ago · accessnewswire.com

Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June ...

3 weeks ago · accessnewswire.com

Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will relea...

3 weeks ago · businesswire.com

Twist Bioscience and Ginkgo Bioworks Revise Collaboration

SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...

4 weeks ago · seekingalpha.com

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Foun...

4 weeks ago · zacks.com

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.

1 month ago · businesswire.com

Twist Bioscience Spins Out DNA Data Storage as Independent Company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

Load More News